Completed PHASE3 INTERVENTIONAL 2-arm NCT00734162

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection

Sponsor: Gilead Sciences

Conditions Hepatitis B Virus (HBV)

Interventions Placebo Tenofovir disoproxil fumarate (TDF)

Updated 7 times since 2017 Last updated: Jul 20, 2016 Started: Dec 31, 2008 Primary completion: Mar 31, 2011 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00734162, this PHASE3 trial focuses on Hepatitis B Virus (HBV) and remains completed. Sponsored by Gilead Sciences, it has been updated 7 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bialystok, Poland , Bron, France , Bucharest, Romania , Bydgoszcz, Poland , Indianapolis, United States , Izmir, Turkey (Türkiye) , Krakow, Poland , Lille, France , Madrid, Spain , Napaco, Romania and 7 more locations